logo
Book a meeting
OncoNano Medicine

Onco Nano Medicine

Biotechnology, 333 Oyster Pt BLVD, Southlake, Texas, 94080, United States, 11-50 Employees

onconanomed.com

  • LinkedIn

Who is ONCONANO MEDICINE

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identi...

Read More

lock icon Get Full Access
map
  • 333 Oyster Pt BLVD, Southlake, Texas, 94080, United States Headquarters: 333 Oyster Pt BLVD, Southlake, Texas, 94080, United States
  • 2008 Date Founded: 2008
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $100 Million to $250 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from ONCONANO MEDICINE

OncoNano Medicine Org Chart and Mapping

Employees
Euodia Jonathan

Euodia Jonathan

Associate Director

Ruolan Han

Ruolan Han

VP of Nonclinical and Translational Medicine

George Pickard

George Pickard

Sr. Director of Finance

See Full Org Chart arrow
email-formate-icon
View Email Formats for OncoNano Medicine
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding OncoNano Medicine

Answer: OncoNano Medicine's headquarters are located at 333 Oyster Pt BLVD, Southlake, Texas, 94080, United States

Answer: OncoNano Medicine's official website is https://onconanomed.com

Answer: OncoNano Medicine's revenue is $100 Million to $250 Million

Answer: OncoNano Medicine's SIC: 2834

Answer: OncoNano Medicine has 11-50 employees

Answer: OncoNano Medicine is in Biotechnology

Answer: OncoNano Medicine contact info: Phone number: Website: https://onconanomed.com

Answer: OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. Our lead program, ONM-100, targets tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access